BTAIQ
BTAIQ clinical trials: BioXcel Therapeutics, Inc.
Every trial on ClinicalTrials.gov where BioXcel Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 15
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BTAIQ on the catalyst calendar · BTAIQ registry changes
- Primary completion Oct 31, 2023ActualPhase 1/Phase 2NCT03910660A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either...BioXcel Therapeutics Inc · Prostate CancerCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2025ActualPhase 2NCT07116694Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderBioXcel Therapeutics Inc · Bipolar I DisorderCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2023ActualPhase 3NCT05665088Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)BioXcel Therapeutics Inc · AgitationTerminatedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2024ActualPhase 4NCT06041646Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderBioXcel Therapeutics Inc · Bipolar DisorderCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2022Sponsor estimatePhase 2NCT05313386Study of BXCL501 In Agitation Associated With Delirium in ICU PatientsBioXcel Therapeutics Inc · AgitationWithdrawnBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2022ActualPhase 2NCT05276830An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaBioXcel Therapeutics Inc · AgitationTerminatedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2023ActualPhase 3NCT05271552Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)BioXcel Therapeutics Inc · AgitationCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2027Sponsor estimatePhase 1NCT05025605Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderBioXcel Therapeutics Inc · SchizophreniaRecruitingBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2021ActualPhase 1/Phase 2NCT04470050Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid WithdrawalBioXcel Therapeutics Inc · Opioid WithdrawalCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 21, 2020ActualPhase 3NCT04276883Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderBioXcel Therapeutics Inc · Agitation Associated With Bipolar DisorderCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2020ActualPhase 3NCT04268303Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaBioXcel Therapeutics Inc · AgitationCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2022ActualPhase 1/Phase 2NCT04251910Sub-Lingual Dexmedetomidine in Agitation Associated With DementiaBioXcel Therapeutics Inc · Agitation,PsychomotorCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2021Sponsor estimateEarly Phase 1NCT04123574A Pilot Study of BXCL701 in Patients With Pancreatic CancerBioXcel Therapeutics Inc · Cancer of PancreasWithdrawnBTAIQLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2019ActualPhase 1NCT04010305Sub-Lingual Dexmedetomidine in Agitation Associated With SchizophreniaBioXcel Therapeutics Inc · AgitationCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2025ActualPhase 3NCT05658510Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)BioXcel Therapeutics Inc · Agitation,PsychomotorCompletedBTAIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025ActualPhase 1/Phase 2NCT05712707Sublingual Dexmedetomidine for Treating Opioid WithdrawalNew York State Psychiatric Institute · Opioid Use DisorderActive, not recruitingBTAIQCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2027Sponsor estimatePhase 1NCT06335407Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient StudyPharmacotherapies for Alcohol and Substance Use Disorders Alliance · Alcohol Use Disorder (AUD)RecruitingBTAIQCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2025ActualPhase 2NCT05558982BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaGeorgetown University · Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingBTAIQCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2021Sponsor estimatePhase 2NCT04382170Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary EfficacyJeff C. Huffman, MD · DeliriumWithdrawnBTAIQCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2, 2023ActualPhase 1NCT04827056Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction StudyPharmacotherapies for Alcohol and Substance Use Disorders Alliance · Alcohol Use Disorder (AUD)CompletedBTAIQCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2024Sponsor estimatePhase 4NCT06093451Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar DisorderTemple University · Schizophrenia AgitationUnknown statusBTAIQCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner